Division of Clinical Biochemistry and Immunology, Department of Laboratory Medicine and Pathology, Mayo Clinic, 200 First St SW, Rochester, MN 55905, USA.
Am J Clin Pathol. 2012 Oct;138(4):609-13. doi: 10.1309/AJCPT6OWWMHITA1Y.
Monoclonal gammopathy of undetermined significance (MGUS) that presents with no quantifiable M spike on immunofixation electrophoresis (IFE) can be termed IFE MGUS. We retrospectively identified patients with IFE MGUS who were monitored with at least 1 subsequent assessment that included an IFE, and evaluated the persistence of the monoclonal protein and the progression of disease. Although the monoclonal proteins persisted in the majority of patients, 16% did not experience this persistence, and had no documented immunomodulatory therapy. After a median follow-up of 3.9 years, the disease clinically progressed in 14 patients (3.2%). Eight of these 14 patients with clinical progression had an immunoglobulin (Ig) A IFE M protein and 6 had an IgG M protein. This study demonstrates that in some patients with IFE MGUS, the M proteins are transient and that IgA IFE MGUS is more likely to persist and progress to myeloma.
意义未明的单克隆丙种球蛋白血症(MGUS),即在免疫固定电泳(IFE)上无可定量的 M 峰者,可称为 IFE-MGUS。我们回顾性地确定了具有 IFE-MGUS 的患者,这些患者至少进行了 1 次后续评估,包括 IFE,并评估了单克隆蛋白的持续存在和疾病的进展情况。尽管大多数患者的单克隆蛋白持续存在,但仍有 16%的患者未出现这种持续性,且未进行免疫调节治疗。中位随访 3.9 年后,14 例患者(3.2%)出现临床进展。在这 14 例临床进展的患者中,8 例有 IgA IFE M 蛋白,6 例有 IgG M 蛋白。本研究表明,在一些 IFE-MGUS 患者中,M 蛋白是一过性的,而 IgA IFE-MGUS 更可能持续存在并进展为骨髓瘤。